In our cohort, CD3+ T cells, CD4+ T cells, CD8+ T cells, CD19+ T cells, and CD16+/ CD56+ NK cells showed significant differences in mild/moderate COVID-19 cases with and without progression. This evidence concerns the gene CD8A and COVID-19.